These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33006180)

  • 1. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Nicol M; Deney A; Lairez O; Vergaro G; Emdin M; Carecci A; Inamo J; Montfort A; Neviere R; Damy T; Harel S; Royer B; Baudet M; Cohen-Solal A; Arnulf B; Logeart D
    Eur J Heart Fail; 2021 Feb; 23(2):231-239. PubMed ID: 33006180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.
    Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D
    Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of Cardiopulmonary Exercise Testing in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Treated With Tafamidis.
    Dalia T; Acharya P; Chan WC; Sauer AJ; Weidling R; Fritzlen J; Goyal A; Miller D; Knipper E; Porter CB; Shah Z
    J Card Fail; 2021 Nov; 27(11):1285-1289. PubMed ID: 34280522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise oscillatory breathing and NT-proBNP levels in stable heart failure provide the strongest prediction of cardiac outcome when combining biomarkers with cardiopulmonary exercise testing.
    Guazzi M; Boracchi P; Labate V; Arena R; Reina G
    J Card Fail; 2012 Apr; 18(4):313-20. PubMed ID: 22464773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
    Vergaro G; Castiglione V; Aimo A; Prontera C; Masotti S; Musetti V; Nicol M; Cohen Solal A; Logeart D; Georgiopoulos G; Chubuchny V; Giannoni A; Clerico A; Buda G; Patel KN; Razvi Y; Patel R; Wechalekar A; Lachmann H; Hawkins PN; Passino C; Gillmore J; Emdin M; Fontana M
    Eur J Heart Fail; 2023 Mar; 25(3):335-346. PubMed ID: 36597836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.
    Patel RK; Bandera F; Venneri L; Porcari A; Razvi Y; Ioannou A; Chacko L; Martinez-Naharro A; Rauf MU; Knight D; Brown J; Petrie A; Wechalekar A; Whelan C; Lachmann H; Muthurangu V; Guazzi M; Hawkins PN; Gillmore JD; Fontana M
    JAMA Cardiol; 2024 Apr; 9(4):367-376. PubMed ID: 38446436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis.
    Silverii MV; Argirò A; Baldasseroni S; Fumagalli C; Zampieri M; Guerrieri L; Bartolini S; Mazzoni C; Burgisser C; Tomberli A; Di Mario C; Marchionni N; Olivotto I; Perfetto F; Fattirolli F; Cappelli F
    Intern Emerg Med; 2023 Mar; 18(2):585-593. PubMed ID: 36396841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters.
    Briasoulis A; Theodorakakou F; Rempakos A; Petropoulos I; Gavriatopoulou M; Androulakis E; Stamatelopoulos K; Kallianos A; Trakada G; Dimopoulos MA; Kastritis E
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.
    Bhutani D; Pan S; Latif F; Goldsmith RL; Saith SE; Mapara MY; Chakraborty R; Lentzsch S; Maurer MS
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):545-548. PubMed ID: 34024744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the transition to and progression of heart failure with preserved ejection fraction: a weighted risk score using bio-humoural, cardiopulmonary, and echocardiographic stress testing.
    Pugliese NR; De Biase N; Gargani L; Mazzola M; Conte L; Fabiani I; Natali A; Dini FL; Frumento P; Rosada J; Taddei S; Borlaug BA; Masi S
    Eur J Prev Cardiol; 2021 Dec; 28(15):1650-1661. PubMed ID: 33624088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease.
    Baggen VJ; van den Bosch AE; Eindhoven JA; Schut AW; Cuypers JA; Witsenburg M; de Waart M; van Schaik RH; Zijlstra F; Boersma E; Roos-Hesselink JW
    Circulation; 2017 Jan; 135(3):264-279. PubMed ID: 27832613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
    PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise Capacity, NT-proBNP, and Exercise Hemodynamics in Adults Post-Fontan.
    Miranda WR; Jain CC; Borlaug BA; Jaffe AS; Connolly HM; Burchill LJ; Egbe AC
    J Am Coll Cardiol; 2023 Apr; 81(16):1590-1600. PubMed ID: 37076213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
    Sharpley FA; Fontana M; Martinez-Naharro A; Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Hawkins PN; Wechalekar AD
    Haematologica; 2020 May; 105(5):1405-1413. PubMed ID: 31399529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
    Emdin M; Aimo A; Vergaro G; Bayes-Genis A; Lupón J; Latini R; Meessen J; Anand IS; Cohn JN; Gravning J; Gullestad L; Broch K; Ueland T; Nymo SH; Brunner-La Rocca HP; de Boer RA; Gaggin HK; Ripoli A; Passino C; Januzzi JL
    J Am Coll Cardiol; 2018 Nov; 72(19):2309-2320. PubMed ID: 30384887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure.
    Vergaro G; Aimo A; Campora A; Castiglione V; Prontera C; Masotti S; Musetti V; Chianca M; Valleggi A; Spini V; Emdin M; Passino C
    Amyloid; 2021 Dec; 28(4):252-258. PubMed ID: 34396857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.